Tags

Type your tag names separated by a space and hit enter

Inositol: history of an effective therapy for Polycystic Ovary Syndrome.
Eur Rev Med Pharmacol Sci 2014; 18(13):1896-903ER

Abstract

Inositol is a physiological compound belonging to the sugar family. The two inositol stereoisomers, myo-inositol and D-chiroinositol are the two main stereisomers present in our body. Myo-inositol is the precursor of inositol triphosphate, a second messenger regulating many hormones such as TSH, FSH and insulin. D-chiroinositol is synthetized by an insulin dependent epimerase that converts myo-inositol into D-chiro-inositol. Polycistic Ovary Syndrome (PCOS) is a metabolic and hormonal disorder and a common cause of infertility. Insulin resistance and the consequent hyperinsulinaemia contribute to hyperandrogenism development, typical marker of PCOS. In these patients myo and/or D-chiro-inositol administration improves insulin sensivity while only myo-inositol is a quality marker for oocytes evaluation. Myo-inositol produces second messengers for FSH and glucose uptake, while D-chiroinositol provides second messengers promoting glucose uptake and glycogen synthesis. The physiological ratio of these two isomers is 40:1 (MI/DCI) and seems to be an optimal approach for the treatment of PCOS disorders.

Links

  • Publisher Full Text

    • Authors+Show Affiliations

    Bizzarri M
    Department of Experimental Medicine, "Sapienza" University of Rome, Rome, Italy. g.carlomagno@lolipharma.it.
    Carlomagno G
    No affiliation info available

    MeSH

    AnimalsFemaleHistory, 19th CenturyHistory, 20th CenturyHistory, 21st CenturyHumansInositolPolycystic Ovary SyndromeVitamin B Complex

    Pub Type(s)

    Historical Article
    Journal Article

    Language

    eng

    PubMed ID

    25010620

    Citation

    Bizzarri, M, and G Carlomagno. "Inositol: History of an Effective Therapy for Polycystic Ovary Syndrome." European Review for Medical and Pharmacological Sciences, vol. 18, no. 13, 2014, pp. 1896-903.
    Bizzarri M, Carlomagno G. Inositol: history of an effective therapy for Polycystic Ovary Syndrome. Eur Rev Med Pharmacol Sci. 2014;18(13):1896-903.
    Bizzarri, M., & Carlomagno, G. (2014). Inositol: history of an effective therapy for Polycystic Ovary Syndrome. European Review for Medical and Pharmacological Sciences, 18(13), pp. 1896-903.
    Bizzarri M, Carlomagno G. Inositol: History of an Effective Therapy for Polycystic Ovary Syndrome. Eur Rev Med Pharmacol Sci. 2014;18(13):1896-903. PubMed PMID: 25010620.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Inositol: history of an effective therapy for Polycystic Ovary Syndrome. AU - Bizzarri,M, AU - Carlomagno,G, PY - 2014/7/11/entrez PY - 2014/7/11/pubmed PY - 2015/4/4/medline SP - 1896 EP - 903 JF - European review for medical and pharmacological sciences JO - Eur Rev Med Pharmacol Sci VL - 18 IS - 13 N2 - Inositol is a physiological compound belonging to the sugar family. The two inositol stereoisomers, myo-inositol and D-chiroinositol are the two main stereisomers present in our body. Myo-inositol is the precursor of inositol triphosphate, a second messenger regulating many hormones such as TSH, FSH and insulin. D-chiroinositol is synthetized by an insulin dependent epimerase that converts myo-inositol into D-chiro-inositol. Polycistic Ovary Syndrome (PCOS) is a metabolic and hormonal disorder and a common cause of infertility. Insulin resistance and the consequent hyperinsulinaemia contribute to hyperandrogenism development, typical marker of PCOS. In these patients myo and/or D-chiro-inositol administration improves insulin sensivity while only myo-inositol is a quality marker for oocytes evaluation. Myo-inositol produces second messengers for FSH and glucose uptake, while D-chiroinositol provides second messengers promoting glucose uptake and glycogen synthesis. The physiological ratio of these two isomers is 40:1 (MI/DCI) and seems to be an optimal approach for the treatment of PCOS disorders. SN - 2284-0729 UR - https://www.unboundmedicine.com/medline/citation/25010620/full_citation L2 - http://www.europeanreview.org/article/7565 DB - PRIME DP - Unbound Medicine ER -